成人癲癇患者共患軀體疾病的抗癲癇藥物選擇_Journal of Epilepsy

Authors：

陳艷艷 ,  林衛紅

吉林大學第一醫院神經內科神經科學中心（長春 130021）;

Corresponding?author：

林衛紅, Email: linweihong321@126.com

Keywords：

癲癇; 軀體疾病; 治療

DOI：

10.7507/2096-0247.20180057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

癲癇共患軀體疾病現象普遍，在治療方面尚無指南或專家共識。文章在檢索癲癇共患病、各臟器疾病與癲癇發作、癲癇的藥物治療等方面文獻之后，對癲癇共患軀體疾病的抗癲癇藥物選擇進行討論，并按照軀體疾病的分類進行綜述，旨在為解決癲癇共患軀體疾病可能遇到的臨床實際問題提供參考，指導臨床用藥。

Citation： 陳艷艷, 林衛紅. 成人癲癇患者共患軀體疾病的抗癲癇藥物選擇. Journal of Epilepsy, 2018, 4(4): 344-350. doi: 10.7507/2096-0247.20180057 Copy

1.	Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol Scand, 2009, 120(1): 1-15.
2.	Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure, 2007, 16(6): 527-532.
3.	Nau KM, Divertie GD, Valentino AK, et al. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care, 2009, 11(1): 34-37.
4.	Kaul S, Meena AK, Murthy JM. Carbamazepine induced bradicardia. Neurol India, 2000, 48(4): 403-404.
5.	Murphy N, Mockler M, Ryder M, et al. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail, 2007, 13(3): 227-279.
6.	Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2003, 2(8): 473-481.
7.	Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure, 2006, 15(3): 156-164.
8.	Ruiz-Gimenez J, Sanchez-Alvarez JC, Canadillas-Hidalgo F, et al. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure, 2010, 19(7): 375-382.
9.	Neuman MG, Nanau RM, Shekh-Ahmad T, et al. Valproic acid derivatives signal for apoptosis and repair in vitro. Clinical Biochem, 2013, 46(15): 1532-1537.
10.	Sasaki E, Iwamura A, Tsuneyama K, et al. Role of cytochrome P450-mediated metabolism and identification of novel thiol conjugated metabolites in mice with phenytoin-induced liver injury. Toxicol Lett, 2015, 232(1): 79-88.
11.	Zheng F, Du C, Wang X. Levetiracetam for the treatment of status epilepticus. Exp Rev Neurother, 2015, 15(10): 1113-1121.
12.	Legros B, Depondt C, Levy-Nogueira M, et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: Comparison of 200 and 400 mg loading doses. Neurocrit Care, 2014, 20(3): 484-488.
13.	Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol, 2017, 77: 23-36.
14.	Delco F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf, 2005, 28(6): 529-545.
15.	Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo controlled safety and pharmacokinetic study. Epilepsia, 2006, 47(7): 1128-1135.
16.	Israni RK, Kasbekar N, Haynes K, et al. Use of antiepileptic drugs in patients with kidney disease. Sem Dialysis, 2006, 19(9): 408-416.
17.	Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf, 2007, 6(5): 547-557.
18.	Szaflarsky JP, Rackley AY, Kleindorfer DO, et al. Incidence of seizures in the acute phase of stroke: A population-based study. Epilepsia, 2008, 49(6): 974-981.
19.	Motika PV, Spencer DC. Treatment of epilepsy in theelderly. Curr Neurol Neurosci Rep, 2016, 16(11): 96.
20.	Zaccara G. Neurological comorbidity and epilepsy: Implications for treatment. Acta Neurol Scand, 2009, 120(1): 1-15.
21.	Koch M, Uyttenboogaart M, Polman S, et al. Seizures in multiple sclerosis. Epilepsia, 2008, 49(6): 948-953.
22.	Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol, 2008, 28(1): 56-68.
23.	Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia, 1993, 34(3): 453-468.
24.	Hommet C, Mondon K, Camus V, et al. Epilepsy and dementia in the elderly. Dement Geriatr Cogn Disord, 2008, 25(4): 293-300.
25.	van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol, 2007, 6(5): 421-430.
26.	Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumours. Cochrane Database Syst Rev, 2008, 2: CD004424.
27.	Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology, 2006, 67(Suppl 4): 10-3.
28.	Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand, 2003, 108(Suppl 180): 16-22.
29.	Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivation. Br J Dermatol, 2007, 156: 1083-1084.
30.	Birbeck GL, French JA, Perucca E, et al. Quality standards subcommittee of the American academy of neurology; Ad Hoc task force of the commission on therapeutic strategies of the International League Against Epilepsy. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILA Eand AAN. Epilepsia, 2012, 53(1): 207-214.
31.	Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology, 2006, 67(Suppl 4): 19-22.
32.	Solinas C, Vajda FJ. Epilepsy and porphyria: new perspectives. J Clin Neurosci, 2004, 11(4): 356-361.
33.	Suzuki A, Aso K, Ariyoshi C, et al. Acute intermittent porphyria and epilepsy: Safety of clonazepam. Epilepsia, 1992, 33(1): 108-111.
34.	Zaatreh MM. Levetiracetam in porphyric status epilepticus: A case report. Clin Neuropharmacol, 2005, 28(5): 243-244.
35.	Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet, 2015, 8: 201-214.
36.	Bernadette GH, Rieck K, Runge U. Oxcarbacepine in focal epilepsy and hepatic porphyria: A case report. Epilepsia, 2001, 42(6): 793-795.
37.	Finsterer J, Zarrouk-Mahjoub S. Management of epilepsy in MERRF syndrome. Seizure, 2017, 50: 166-170.
38.	Kang HC, Lee YM, Kim HD. Mitochondrial disease and epilepsy. Brain Dev, 2013, 35(8): 757-761.
39.	Vainionp?? LK, Mikkonen K, Ratty? J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia, 2004, 45(3): 197-203.
40.	Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology, 2008, 70(18): 1586-1593.
41.	Ben-Menachem E. Weight issues for people with epilepsy: A review. Epilepsia, 2007, 48(Suppl 9): 42-45.

1. Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol Scand, 2009, 120(1): 1-15.
2. Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure, 2007, 16(6): 527-532.
3. Nau KM, Divertie GD, Valentino AK, et al. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care, 2009, 11(1): 34-37.
4. Kaul S, Meena AK, Murthy JM. Carbamazepine induced bradicardia. Neurol India, 2000, 48(4): 403-404.
5. Murphy N, Mockler M, Ryder M, et al. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail, 2007, 13(3): 227-279.
6. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2003, 2(8): 473-481.
7. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure, 2006, 15(3): 156-164.
8. Ruiz-Gimenez J, Sanchez-Alvarez JC, Canadillas-Hidalgo F, et al. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure, 2010, 19(7): 375-382.
9. Neuman MG, Nanau RM, Shekh-Ahmad T, et al. Valproic acid derivatives signal for apoptosis and repair in vitro. Clinical Biochem, 2013, 46(15): 1532-1537.
10. Sasaki E, Iwamura A, Tsuneyama K, et al. Role of cytochrome P450-mediated metabolism and identification of novel thiol conjugated metabolites in mice with phenytoin-induced liver injury. Toxicol Lett, 2015, 232(1): 79-88.
11. Zheng F, Du C, Wang X. Levetiracetam for the treatment of status epilepticus. Exp Rev Neurother, 2015, 15(10): 1113-1121.
12. Legros B, Depondt C, Levy-Nogueira M, et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: Comparison of 200 and 400 mg loading doses. Neurocrit Care, 2014, 20(3): 484-488.
13. Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol, 2017, 77: 23-36.
14. Delco F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf, 2005, 28(6): 529-545.
15. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo controlled safety and pharmacokinetic study. Epilepsia, 2006, 47(7): 1128-1135.
16. Israni RK, Kasbekar N, Haynes K, et al. Use of antiepileptic drugs in patients with kidney disease. Sem Dialysis, 2006, 19(9): 408-416.
17. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf, 2007, 6(5): 547-557.
18. Szaflarsky JP, Rackley AY, Kleindorfer DO, et al. Incidence of seizures in the acute phase of stroke: A population-based study. Epilepsia, 2008, 49(6): 974-981.
19. Motika PV, Spencer DC. Treatment of epilepsy in theelderly. Curr Neurol Neurosci Rep, 2016, 16(11): 96.
20. Zaccara G. Neurological comorbidity and epilepsy: Implications for treatment. Acta Neurol Scand, 2009, 120(1): 1-15.
21. Koch M, Uyttenboogaart M, Polman S, et al. Seizures in multiple sclerosis. Epilepsia, 2008, 49(6): 948-953.
22. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol, 2008, 28(1): 56-68.
23. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia, 1993, 34(3): 453-468.
24. Hommet C, Mondon K, Camus V, et al. Epilepsy and dementia in the elderly. Dement Geriatr Cogn Disord, 2008, 25(4): 293-300.
25. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol, 2007, 6(5): 421-430.
26. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumours. Cochrane Database Syst Rev, 2008, 2: CD004424.
27. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology, 2006, 67(Suppl 4): 10-3.
28. Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand, 2003, 108(Suppl 180): 16-22.
29. Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivation. Br J Dermatol, 2007, 156: 1083-1084.
30. Birbeck GL, French JA, Perucca E, et al. Quality standards subcommittee of the American academy of neurology; Ad Hoc task force of the commission on therapeutic strategies of the International League Against Epilepsy. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILA Eand AAN. Epilepsia, 2012, 53(1): 207-214.
31. Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology, 2006, 67(Suppl 4): 19-22.
32. Solinas C, Vajda FJ. Epilepsy and porphyria: new perspectives. J Clin Neurosci, 2004, 11(4): 356-361.
33. Suzuki A, Aso K, Ariyoshi C, et al. Acute intermittent porphyria and epilepsy: Safety of clonazepam. Epilepsia, 1992, 33(1): 108-111.
34. Zaatreh MM. Levetiracetam in porphyric status epilepticus: A case report. Clin Neuropharmacol, 2005, 28(5): 243-244.
35. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet, 2015, 8: 201-214.
36. Bernadette GH, Rieck K, Runge U. Oxcarbacepine in focal epilepsy and hepatic porphyria: A case report. Epilepsia, 2001, 42(6): 793-795.
37. Finsterer J, Zarrouk-Mahjoub S. Management of epilepsy in MERRF syndrome. Seizure, 2017, 50: 166-170.
38. Kang HC, Lee YM, Kim HD. Mitochondrial disease and epilepsy. Brain Dev, 2013, 35(8): 757-761.
39. Vainionp?? LK, Mikkonen K, Ratty? J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia, 2004, 45(3): 197-203.
40. Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology, 2008, 70(18): 1586-1593.
41. Ben-Menachem E. Weight issues for people with epilepsy: A review. Epilepsia, 2007, 48(Suppl 9): 42-45.

Previous Article
癲癇合并阻塞性睡眠呼吸暫停綜合征相關危險因素的研究進展
Next Article
法國立體定向腦電圖指南：編者按

Journal of Epilepsy

成人癲癇患者共患軀體疾病的抗癲癇藥物選擇

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content